1062P EGFR-XPAT, a novel pro-drug T-cell engager (TCEs) engineered to address on-target, off-tumour toxicity and an orthogonal approach for cancer immunotherapy in EGFR, KRAS/BRAF cancers

Autor:	A. Henkensiefken, M. Hammond, A. Nazeer, F. Cattaruzza, V. Schellenberger, B. Irving, C. Koski, Z. Lange, Mika K. Derynck, B-C. Sim
Rok vydání:	2020
Předmět:	business.industry medicine.medical_treatment T cell Hematology Prodrug medicine.disease_cause medicine.anatomical_structure Oncology Cancer immunotherapy Toxicity medicine Cancer research KRAS business
Zdroj:	Annals of Oncology. 31:S724
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.1182
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2e456faa8096fb0d221afa0a40a0828b https://doi.org/10.1016/j.annonc.2020.08.1182 Zobrazit plný text záznamu